![Placeholder Image Placeholder Image](https://prod.arctic.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis announces European Commission approval of Beovu® for people living with diabetic macular edema
-
Media ReleaseNovartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
-
Media ReleaseUS FDA approves updated Novartis Beovu® label, to include additional safety information
-
Media ReleaseNew Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus aflibercept